Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -36.79% is 43% above its 3-year average of -65.11%, near the high end of its 3-year range (-119.40%–-36.79%).
As of the fiscal period ended Tuesday, June 30, 2026. 33.77% above its 12-month average of -55.56%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -36.79%.
RETURN ON EQUITY (ROE)
-36.79%
RETURN ON EQUITY (ROE) AVG TTM
-55.56%
RETURN ON EQUITY (ROE) AVG 3Y
-65.11%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+33.77%
CURRENT VS 3Y AVG
+43.49%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.89%
median of 684 covered companies
CURRENT VS SECTOR MEDIAN
+10.02%
vs the sector median at left
Oculis Holding AG
Market Cap
$495.60M
Return on Equity (ROE)
-36.79%
TTM Avg
-55.56%
3Y Avg
-65.11%
5Y Avg
N/A
Market Cap
$490.41M
Return on Equity (ROE)
N/A
TTM Avg
-344.79%
3Y Avg
-198.42%
5Y Avg
-104.57%
Market Cap
$486.35M
Return on Equity (ROE)
19.28%
TTM Avg
28.37%
3Y Avg
24.29%
5Y Avg
382.68%
Market Cap
$509.10M
Return on Equity (ROE)
-37.94%
TTM Avg
-63.13%
3Y Avg
-60.30%
5Y Avg
-47.34%
Market Cap
$509.56M
Return on Equity (ROE)
-27.20%
TTM Avg
-44.25%
3Y Avg
-32.03%
5Y Avg
-24.61%
Market Cap
$509.80M
Return on Equity (ROE)
-99.83%
TTM Avg
118.83%
3Y Avg
8.21%
5Y Avg
-14.12%
Market Cap
$478.01M
Return on Equity (ROE)
1.65%
TTM Avg
-27.02%
3Y Avg
-39.92%
5Y Avg
-33.78%
Market Cap
$475.60M
Return on Equity (ROE)
-9.69%
TTM Avg
-30.79%
3Y Avg
-49.02%
5Y Avg
-53.00%
Market Cap
$472.03M
Return on Equity (ROE)
-8.21%
TTM Avg
-32.76%
3Y Avg
-79.80%
5Y Avg
-71.61%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oculis Holding AG (OCS) | $495.60M | -36.79% | -55.56% | -65.11% | N/A |
| Evolus, Inc. (EOLS)vs › | $490.41M | N/A | -344.79% | -198.42% | -104.57% |
| Puma Biotechnology, Inc. (PBYI)vs › | $486.35M | 19.28% | 28.37% | 24.29% | 382.68% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $509.10M | -37.94% | -63.13% | -60.30% | -47.34% |
| 908 Devices Inc. (MASS)vs › | $509.56M | -27.20% | -44.25% | -32.03% | -24.61% |
| Crescent Biopharma, Inc. (CBIO)vs › | $509.80M | -99.83% | 118.83% | 8.21% | -14.12% |
| Arvinas, Inc. (ARVN)vs › | $478.01M | 1.65% | -27.02% | -39.92% | -33.78% |
| Cerus Corporation (CERS)vs › | $475.60M | -9.69% | -30.79% | -49.02% | -53.00% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $472.03M | -8.21% | -32.76% | -79.80% | -71.61% |
| Altimmune, Inc. (ALT)vs › | $515.36M | -19.35% | -58.07% | -51.86% | -46.32% |
ROE
-36.8%
ROA
-32.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -36.79% |
| 2026-03-31 | -48.71% |
| 2025-12-31 | -48.50% |
| 2025-09-30 | -74.54% |
| 2025-06-30 | -69.24% |
| 2025-03-31 | -63.23% |
| 2024-12-31 | -119.40% |
| 2024-09-30 | -70.98% |
| 2024-06-30 | -59.53% |
| 2024-03-31 | -75.43% |
| 2023-12-31 | -88.49% |
| 2023-09-30 | -81.14% |
| 2023-06-30 | -64.68% |
